FDA
-
-
-
-
-
-
-
Arvinas to Present at Jefferies Global Healthcare Conference
-
-
-
-
-
-
-
Arvinas shares gain as FDA approves breast cancer drug Veppanu
-
-
-
-
-
-
-
Arvinas Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
FDA accepts Arvinas drug application for advanced breast cancer treatment
-
-
-
-
-
-
-
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
-
-
-
-
-
-
-
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
-
-
-
-
-
-
-
Arvinas Announces Upcoming Vepdegestrant Poster Presentations at the 2024 San Antonio Breast Cancer Symposium
-
330,671 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

